Product Background: Sphingosine 1-Phosphate (S1P) is a key component of the sphingolipid signaling cascade. S1P initiates a proliferative, pro-angiogenic and anti-apoptotic sequence of events contributing to cancer progression. Recently, scientific literature has suggested that S1P is a potent tumorigenic growth factor that is likely released from tumor cells and that S1P may be a novel biomarker for early stage cancer detection. Sphingosine kinase has also been shown to be up-regulated in a variety of cancer types. S1P antibody (LT1002) was originally developed and patented at Lpath Therapeutics.
Storage
Antibody is stable for up to 1 year at -20 °C. Antibody is stable for 60 days at 4°C. Avoid repeated freeze/thaw cycles.
Powered by Bioz See more details on Bioz
References
1) Visentin B, Reynolds G, Sabbadini R. (2012) Immunohistochemical detection of sphingosine-1-phosphate and sphingosine kinase-1 in human tissue samples. Methods Mol Biol. 874:55-67.2) O’Brien N, Jones ST, Williams DG, Cunningham HB, Moreno K, Visentin B, et al. (2009) Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. J Lipid Res.;50(11):2245-57.3) Swaney JS, Moreno KM, Gentile AM, Sabbadini RA, Stoller GL. (2008) Sphingosine-1-phosphate (S1P) is a novel fibrotic mediator in the eye. Exp Eye Res.;87(4):367-75.
Bulk discounts available, please email echelon@echelon-inc.com for information.